Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) signalling exerts chondrogenesis promoting and protecting effects: Implication of calcineurin as a downstream target

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Juhász, Tamás ^a   Matta, Csaba ^a   Katona, Éva ^a   Somogyi, Csilla ^a   Takács, Roland ^a   Gergely, Pál ^b   Csernoch, László ^a   Panyi, Gyorgy ^a   Tóth, Gábor ^c   Reglodi, Dóra ^d   Tamás, Andrea ^d   Zákány, Róza ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALMODULIN; DUAL SPECIFICITY PHOSPHATASE 2; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MESSENGER RNA; TRANSCRIPTION FACTOR SOX9; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; CALCINEURIN INHIBITOR; CYCLOSPORIN; HYDROGEN PEROXIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; PEPTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL VIABILITY; CHONDROGENESIS; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PAC1 GENE; PACAP GENE; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; VPAC1 GENE; VPAC2 GENE; ANIMAL; CELL PROLIFERATION; CHICK EMBRYO; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; LIMB BUD; METABOLISM; PRIMARY CELL CULTURE; SYNTHESIS;

ANIMALS; CALCINEURIN; CALCINEURIN INHIBITORS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHICK EMBRYO; CHONDROCYTES; CHONDROGENESIS; CYCLOSPORINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HYDROGEN PEROXIDE; LIMB BUDS; OXIDATIVE STRESS; PEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PRIMARY CELL CULTURE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR;

EID: 84898603514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091541     Document Type: Article

References (75)

1. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, et al. (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164: 567-574. (Pubitemid 19269770)
2. Shpakov AO, Derkach KV, Chistiakova OV, Bondareva VM (2011) [Functional state of adenylate cyclase signaling system in testis and ovary of fasted rats]. Zh Evol Biokhim Fiziol 47: 40-48.
3. Pirone A, Baoan D, Piano I, Santina LD, Baglini A, et al. (2011) Pituitary adenylate cyclase-activating peptide (PACAP) immunoreactivity distribution in the small intestine of the adult New Hampshire chicken. Acta Histochem 113: 477-483.
4. Reglodi D, Kiss P, Horvath G, Lubics A, Laszlo E, et al. (2011) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46:61-70.
5. Reglodi D, Gyarmati J, Ertl T, Borzsei R, Bodis J, et al. (2010) Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth. J Endocrinol Invest 33: 443-445.
6. Borzsei R, Mark L, Tamas A, Bagoly T, Bay C, et al. (2009) Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur J Endocrinol 160: 561-565.
7. Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, et al. (2009) cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells. J Cell Physiol 221: 75-83.
8. Persson E, Lerner UH (2011) The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. J Cell Biochem 112: 3732-3741.
9. Strange-Vognsen HH, Arnbjerg J, Hannibal J (1997) Immunocytochemical demonstration of pituitary adenylate cyclase activating polypeptide (PACAP) in the porcine epiphyseal cartilage canals. Neuropeptides 31: 137-141. (Pubitemid 27240054)
10. Lacombe A, Lelievre V, Roselli CE, Salameh W, Lue YH, et al. (2006) Delayed testicular aging in pituitary adenylate cyclase-activating peptide (PACAP) null mice. Proc Natl Acad Sci U S A 103: 3793-3798. (Pubitemid 43376634)
11. Racz B, Horvath G, Faluhelyi N, Nagy AD, Tamas A, et al. (2008) Effects of PACAP on the circadian changes of signaling pathways in chicken pinealocytes. J Mol Neurosci 36: 220-226.
12. Nakamachi T, Farkas J, Watanabe J, Ohtaki H, Dohi K, et al. (2011) Role of PACAP in neural stem/progenitor cell and astrocyte-from neural development to neural repair. Curr Pharm Des 17: 973-984.
13. Cochaud S, Chevrier L, Meunier AC, Brillet T, Chadeneau C, et al. (2010) The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration. Neuropeptides 44: 373-383.
14. Sanchez A, Chiriva-Internati M, Grammas P (2008) Transduction of PACAP38 protects primary cortical neurons from neurotoxic injury. Neurosci Lett 448: 52-55.
15. Sanchez A, Rao HV, Grammas P (2009) PACAP38 protects rat cortical neurons against the neurotoxicity evoked by sodium nitroprusside and thrombin. Regul Pept 152: 33-40.
16. Shioda S, Ohtaki H, Nakamachi T, Dohi K, Watanabe J, et al. (2006) Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann N Y Acad Sci 1070: 550-560. (Pubitemid 44126702)
17. Horvath G, Reglodi D, Opper B, Brubel R, Tamas A, et al. (2010) Effects of PACAP on the oxidative stress-induced cell death in chicken pinealocytes is influenced by the phase of the circadian clock. Neurosci Lett 484: 148-152.
18. Horvath G, Mark L, Brubel R, Szakaly P, Racz B, et al. (2010) Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci Lett 469: 70-74.
19. Masmoudi-Kouki O, Douiri S, Hamdi Y, Kaddour H, Bahdoudi S, et al. (2011) Pituitary adenylate cyclase-activating polypeptide protects astroglial cells against oxidative stress-induced apoptosis. J Neurochem 117: 403-411.
20. Jolivel V, Basille M, Aubert N, de JS, Ancian P, Le Bigot JF, et al. (2009) Distribution and functional characterization of pituitary adenylate cyclaseactivating polypeptide receptors in the brain of non-human primates. Neuroscience 160: 434-451.
21. Gourlet P, Vandermeers A, Vertongen P, Rathe J, De NP, et al. (1997) Development of high affinity selective VIP1 receptor agonists. Peptides 18: 1539-1545. (Pubitemid 28132996)
22. Vandermeers A, Vandenborre S, Hou X, De NP, Robberecht P, et al. (1992) Antagonistic properties are shifted back to agonistic properties by further Nterminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes. Eur J Biochem 208: 815-819.
23. Laburthe M, Couvineau A, Tan V (2007) Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28: 1631-1639. (Pubitemid 47371033)
24. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, et al. (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61: 283-357.
25. McIlvain HB, Baudy A, Sullivan K, Liu D, Pong K, et al. (2006) Pituitary adenylate cyclase-activating peptide (PACAP) induces differentiation in the neuronal F11 cell line through a PKA-dependent pathway. Brain Res 1077: 16-23.
26. Henrotin YE, Bruckner P, Pujol JP (2003) The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 11: 747-755. (Pubitemid 37184493)
27. Henrotin Y, Kurz B, Aigner T (2005) Oxygen and reactive oxygen species in cartilage degradation: friends or foes? Osteoarthritis Cartilage 13: 643-654.
28. Tiku ML, Liesch JB, Robertson FM (1990) Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines. J Immunol 145: 690-696. (Pubitemid 20252381)
29. Del CM, Jr., Loeser RF (2002) Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen species. Arthritis Rheum 46: 394-403. (Pubitemid 34136577)
30. Brandl A, Hartmann A, Bechmann V, Graf B, et al. (2011) Oxidative stress induces senescence in chondrocytes. J Orthop Res 29: 1114-1120.
31. Zakany R, Szijgyarto Z, Matta C, Juhasz T, Csortos C, et al. (2005) Hydrogen peroxide inhibits formation of cartilage in chicken micromass cultures and decreases the activity of calcineurin: implication of ERK1/2 and Sox9 pathways. Exp Cell Res 305: 190-199. (Pubitemid 40380665)
32. Jovanovic DV, Mineau F, Notoya K, Reboul P, Martel-Pelletier J, et al. (2002) Nitric oxide induced cell death in human osteoarthritic synoviocytes is mediated by tyrosine kinase activation and hydrogen peroxide and/or superoxide formation. J Rheumatol 29: 2165-2175.
33. Tsuji G, Koshiba M, Nakamura H, Kosaka H, Hatachi S, et al. (2006) Thioredoxin protects against joint destruction in a murine arthritis model. Free Radic Biol Med 40: 1721-1731.
34. Ahrens PB, Solursh M, Reiter RS (1977) Stage-related capacity for limb chondrogenesis in cell culture. Dev Biol 60: 69-82. (Pubitemid 8185563)
35. Hadhazy C, Lazlo MB, Kostenszky KS (1982) Cartilage differentiation in micromass cultures of chicken limb buds. Acta Morphol Acad Sci Hung 30: 65-78. (Pubitemid 12059393)
36. Zakany R, Szucs K, Bako E, Felszeghy S, Czifra G, et al. (2002) Protein phosphatase 2A is involved in the regulation of protein kinase A signaling pathway during in vitro chondrogenesis. Exp Cell Res 275: 1-8.
37. de CB, Lefebvre V, Behringer RR, Bi W, Murakami S, et al. (2000) Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol 19: 389-394.
38. Matta C, Juhasz T, Szijgyarto Z, Kolozsvari B, Somogyi C, et al. (2011) PKCdelta is a positive regulator of chondrogenesis in chicken high density micromass cell cultures. Biochimie 93: 149-159.
39. Huang W, Zhou X, Lefebvre V, de CB (2000) Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol 20: 4149-4158. (Pubitemid 30314512)
40. Lee YA, Kang SS, Baek SH, Jung JC, Jin EJ, et al. (2007) Redifferentiation of dedifferentiated chondrocytes on chitosan membranes and involvement of PKCalpha and P38 MAP kinase. Mol Cells 24: 9-15. (Pubitemid 47554787)
41. Rusnak F, Mertz P (2000) Calcineurin: form and function. Physiol Rev 80: 1483-1521.
42. Tomita M, Reinhold MI, Molkentin JD, Naski MC (2002) Calcineurin and NFAT4 induce chondrogenesis. J Biol Chem 277:42214-42218. (Pubitemid 35257540)
43. Matta C, Fodor J, Szijgyarto Z, Juhasz T, Gergely P, et al. (2008) Cytosolic free Ca2+ concentration exhibits a characteristic temporal pattern during in vitro cartilage differentiation: a possible regulatory role of calcineurin in Ca-signalling of chondrogenic cells. Cell Calcium 44: 310-323.
44. Zhou CJ, Yada T, Kohno D, Kikuyama S, Suzuki R, et al. (2001) PACAP activates PKA, PKC and Ca(2+) signaling cascades in rat neuroepithelial cells. Peptides 22: 1111-1117.
45. Zhao L, Li G, Zhou GQ (2009) SOX9 directly binds CREB as a novel synergism with the PKA pathway in BMP-2-induced osteochondrogenic differentiation. J Bone Miner Res 24: 826-836.
46. Kano M, Shimizu Y, Suzuki Y, Furukawa Y, Ishida H, et al. (2011) Pituitary adenylatecyclase-activating polypeptide-immunoreactive nerve fibers in the rat epiglottis and pharynx. Ann Anat 193: 494-499.
47. Horvath G, Brubel R, Kovacs K, Reglodi D, Opper B, et al. (2011) Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells. J Mol Neurosci 43: 67-75.
48. Racz B, Gasz B, Borsiczky B, Gallyas F, Jr., Tamas A, et al. (2007) Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp Endocrinol 153: 115-123. (Pubitemid 47103325)
49. Koelling S, Kruegel J, Irmer M, Path JR, Sadowski B, et al. (2009) Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell 4: 324-335.
50. Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, et al. (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233: 125-128. (Pubitemid 27418180)
51. Kovacs CS, Chik CL, Li B, Karpinski E, Ho AK (1996) Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells. J Endocrinol 149: 287-295. (Pubitemid 26174824)
52. Fodor J, Matta C, Juhasz T, Olah T, Gonczi M, et al. (2009) Ionotropic purinergic receptor P2X4 is involved in the regulation of chondrogenesis in chicken micromass cell cultures. Cell Calcium 45: 421-430.
53. Varga Z, Juhasz T, Matta C, Fodor J, Katona E, et al. (2011) Switch of voltagegated K+ channel expression in the plasma membrane of chondrogenic cells affects cytosolic Ca2+-oscillations and cartilage formation. PLoS One 6: e27957.
54. Vincze A, Reglodi D, Helyes Z, Hashimoto H, Shintani N, et al. (2011) Role of endogenous pituitary adenylate cyclase activating polypeptide (PACAP) in myelination of the rodent brain: lessons from PACAP-deficient mice. Int J Dev Neurosci 29: 923-935.
55. Sherwood NM, Adams BA, Isaac ER, Wu S, Fradinger EA (2007) Knocked down and out: PACAP in development, reproduction and feeding. Peptides 28: 1680-1687. (Pubitemid 47361410)
56. Bergstrom AL, Hannibal J, Hindersson P, Fahrenkrug J (2003) Light-induced phase shift in the Syrian hamster (Mesocricetus auratus) is attenuated by the PACAP receptor antagonist PACAP6-38 or PACAP immunoneutralization. Eur J Neurosci 18: 2552-2562. (Pubitemid 37452671)
57. Reglodi D, Borzsei R, Bagoly T, Boronkai A, Racz B, et al. (2008) Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells. J Mol Neurosci 36: 270-278.
58. Walker CS, Sundrum T, Hay DL (2013) PACAP receptor pharmacology and agonist bias: Analysis in primary neurons and glia from the trigeminal ganglia and transfected cells. Br J Pharmacol. doi: 10.1111/bph.12541
59. Moody TW, Leyton J, Jensen RT (2012) Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin. J Mol Neurosci 46:68-74.
60. Di Michele M, Peeters K, Loyen S, Thys C, Waelkens E, et al. (2012) Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) impairs the regulation of apoptosis in megakaryocytes by activating NF-kB: a proteomic study. Mol Cell Proteomics 11(1):M111.007625.
61. St Hilaire RC, Murthy SN, Kadowitz PJ, Jeter JR, Jr. (2010) Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. Peptides 31: 1517-1522.
62. Njaine B, Martins RA, Santiago MF, Linden R, Silveira MS (2010) Pituitary adenylyl cyclase-activating polypeptide controls the proliferation of retinal progenitor cells through downregulation of cyclin D1. Eur J Neurosci 32: 311-321.
63. Cohen JR, Resnick DZ, Niewiadomski P, Dong H, Liau LM, et al. (2010) Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. BMC Cancer 10: 676.
64. Gasz B, Racz B, Roth E, Borsiczky B, Ferencz A, et al. (2006) Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stressinduced apoptosis. Peptides 27: 87-94. (Pubitemid 43061041)
65. Ushiyama M, Ikeda R, Sugawara H, Yoshida M, Mori K, Kangawa K, et al. (2007) Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third intracellular loop. Mol Pharmacol 72: 103-111. (Pubitemid 46998529)
66. Sun C, Song D, vis-Taber RA, Barrett LW, Scott VE, et al. (2007) Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci U S A 104: 7875-7880. (Pubitemid 47185844)
67. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52: 269-324. (Pubitemid 30368434)
68. Hinoi E, Ueshima T, Hojo H, Iemata M, Takarada T, et al. (2006) Upregulation of per mRNA expression by parathyroid hormone through a protein kinase A-CREB-dependent mechanism in chondrocytes. J Biol Chem 281: 23632-23642. (Pubitemid 44274138)
69. Lam SY, Liu Y, Liong EC, Tipoe GL, Fung ML (2012) Upregulation of pituitary adenylate cyclase activating polypeptide and its receptor expression in the rat carotid body in chronic and intermittent hypoxia. Adv Exp Med Biol 758:301-306.
70. Nakamachi T, Tsuchida M, Kagami N, Yofu S, Wada Y, et al. (2012) IL-6 and PACAP receptor expression and localization after global brain ischemia in mice. J Mol Neurosci 48(3):518-525.
71. Juhasz T, Matta C, Mészár Z, Nagy G, Szijgyarto Z, et al. (2010). Optimalized transient transfection of chondrogenic primary cell cultures. CEJB 5: 572-584.
72. Holighaus Y, Mustafa T, Eiden LE (2011) PAC1hop, null and hip receptors mediate differential signaling through cyclic AMP and calcium leading to splice variant-specific gene induction in neural cells. Peptides 32: 1647-1655.
73. Reinhold MI, Abe M, Kapadia RM, Liao Z, Naski MC (2004) FGF18 represses noggin expression and is induced by calcineurin. J Biol Chem 279: 38209-38219. (Pubitemid 39295968)
74. Khan AM, Li M, Brant E, Maderdrut JL, Majid DS, et al. (2011) Renoprotection with pituitary adenylate cyclase-activating polypeptide in cyclosporine A-induced nephrotoxicity. J Investig Med 59:793-802.
75. Payet MD, Bilodeau L, Breault L, Fournier A, Yon L, et al. (2003) PAC1 receptor activation by PACAP-38 mediates Ca2+ release from a cAMPdependent pool in human fetal adrenal gland chromaffin cells. J Biol Chem 278: 1663-1670. (Pubitemid 36801398)